Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 1
Submit an article Journal homepage
1,958
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Yafit Segmana Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9059-3887
ORCID Icon,
Elena Ribakovskyb Hematology Division, Chaim Sheba Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Ramat Gan, Israel
,
Abraham Avigdorb Hematology Division, Chaim Sheba Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Ramat Gan, Israel
,
Yair Goldhechta Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Vladimir Vainsteinc Hematology Division, Hadassah Medical Center and the Hebrew University Faculty of Medicine, The Hebrew University, Jerusalem, Israel
,
Neta Goldschmidtc Hematology Division, Hadassah Medical Center and the Hebrew University Faculty of Medicine, The Hebrew University, Jerusalem, Israel
,
Shimrit Harlevd Department of Hematology, Rambam Healthcare Campus, Haifa and the Rappaport Faculty of medicine of the Technion, Haifa, Israel
,
Netanel Horwitzd Department of Hematology, Rambam Healthcare Campus, Haifa and the Rappaport Faculty of medicine of the Technion, Haifa, Israel
,
Odit Gutweine Department of Hematology, Assaf Harofeh Medical Center, Tzrifin, Israel
,
Ronit Gurionf Institute of Hematology, Rabin Medical Center, Petch Tikvah, Israel
,
Gilad Itchakif Institute of Hematology, Rabin Medical Center, Petch Tikvah, Israel
,
Uri Abadig Department of Hematology, Meir Medical Center, Kfar Saba, Israel
,
Anatoly Nemetsh Department of Hematology, Barzilai Medical Center, Ashkelon, Israel
,
Orit Soferi Institute of Hematology, Hillel Yaffe Medical Center, Hadera, Israel
,
Miri Zektserj Department of Hematology, Soroka University Medical Center, Negev Beer Sheva, Israel
,
Tamar Tadmork Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel
,
Nagib Dallyl Hematology Unit, Ziv Medical Center, Zefat, Israel
,
Kalman Filanovskym Hematology Unit, Kaplan Medical Center, Rehovot, Israel
,
Merav Leiban Assuta Medical Center, Hematology Institute, Ashdod, Israel
,
Nadav Sarida Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Noam Benyaminia Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Yair Herishanua Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Ron Rama Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Chava Perrya Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
&
Irit Avivia Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
 show all
Pages 118-124 | Received 04 Jun 2020, Accepted 05 Sep 2020, Published online: 27 Sep 2020

References

  • Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
  • Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
  • Sehn L, Herrera A, Flowers C, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Cin Oncol. 2020;38(2):155–165.
  • Herrera A, Ogbu U, Ku G, et al. Real world Bendamustine use in relapsed/refractory diffuse large B cell lymphoma. Hematol Oncol. 2019; 37:428–429.
  • Mounier N, Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726–1731.
  • Witzig T, Vose J, Zinzani P, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622–1627.
  • Landsburg D, Hughes M, Koike A, et al. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. Blood Adv. 2019;3(2):132–135.
  • Wilson W, Young R, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926.
  • Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182(5):633–643.
  • Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009; 114(13):2721–2729.
  • Palanca-Wessels M, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–715.
  • Hans C, Weisenburger D, Greiner T, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
  • Cheson B, Fisher R, Barrington S, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Davids M, Roberts A, Seymour J, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833.
  • Morschhauser F, Flinn I, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–e265.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.